Strategic analysis of the pharma business
In volatile markets pharma landscape is changing with an increasing speed and strategies become also unexpectedly out of date or eviscerated. Population chenges, disease and economic epidemiology seem currently rather foreseeable and the need for effective and safe drugs is bigger than ever. Still cost containment prevails as well as unwillingness to support incremental innovation may be fading in the world where the lead and development times are typically very long. Furthermore, the number of drugs in phase I & II development is all time high but still drugs in late phase development as well as the introduction of new drugs into the market is plateau. Here the pharma terrain is becoming foggy.
Become familiar with the landscape and main change drivers with our complimentary report “Strategic analysis of the pharma business“,which will be periodically updated.
Please visit our site and download at M.I.T. Reports.